Table 1.

Neuropsychiatric Inventory (NPI) domain scores at baseline and at post-16 weeks of open-label risperidone treatment in the combined sample of 110 responders who were randomized to subsequent 16 weeks of continuation risperidone (n=70) or discontinuation to placebo (n=40).

	NPI Domains	Symptom Present Total ‘n’=110		Relapsed at week 32, %			Fisher’s exact test (p-value)
		N	%	NONE	Mild	Severe
Baseline (Week=0)	Hallucinations**	43	39.1	35.8	36	77.8	0.005
	Delusions	95	86.4	33.3	35.1	50	0.28
	Agitation/Aggression	102	92.7	75	35.4	44.4	0.10
	Depression/Dysphoria	48	43.6	38.7	46.3	57.1	0.50
	Anxiety	56	50.9	50	32.5	43.8	0.23
	Elation/Euphoria	8	7.3	44.1	33.3	0	0.60
	Apathy/Indifference	44	40.0	43.9	34.6	50	0.59
	Disinhibition	53	48.2	42.1	44.7	40	0.96
	Irritability/Lability	82	74.5	35.7	42.6	48.6	0.59
	Aberrant Motor	45	40.9	41.5	47.6	41.7	0.93
	Sleep	47	42.7	41.3	42.9	47.4	0.90
	Appetite	29	26.4	43.2	30	66.7	0.19
Randomization (Week=16)	Hallucinations	15	13.6	42.1	46.7	0	0.78
	Delusions	36	32.7	45.9	39.4	0	0.32
	Agitation/Aggression	50	45.5	45	40.4	33.3	0.87
	Depression/Dysphoria	20	18.2	40	50	100	0.20
	Anxiety	33	30.0	40.3	46.9	100	0.39
	Elation/Euphoria	1	0.9	43.1	0	0	1.00
	Apathy/Indifference	42	38.2	42.6	48.3	30.8	0.58
	Disinhibition**	15	13.6	38.9	71.4	0	0.04
	Irritability/Lability	40	36.4	48.6	32.5	0	0.11
	Aberrant Motor	33	30.0	44.2	37.5	44.4	0.90
	Sleep*	20	18.2	47.8	17.6	33.3	0.04
	Appetite	18	16.4	41.3	41.7	66.7	0.61

^**p <0.01,

^*p <0.05.